Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in Early Stage AR(+) Triple Negative Breast Cancer
NCT02750358Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2016
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in triple-negative breast cancer (TNBC), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2016; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02750358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02750358.